Sernova (TSE:SVA) Trading Down 18.5% – Here’s Why

Shares of Sernova Corp. (TSE:SVA) dropped 18.5% during trading on Monday . The stock traded as low as C$0.11 and last traded at C$0.11. 674,159 shares traded hands during mid-day trading, an increase of 415% from the average daily volume of 130,839 shares. The stock had previously closed at C$0.14.

Sernova Stock Down 14.8%

The company has a current ratio of 0.03, a quick ratio of 18.11 and a debt-to-equity ratio of -21.98. The business’s fifty day moving average price is C$0.12 and its 200 day moving average price is C$0.14. The company has a market capitalization of C$43.43 million, a P/E ratio of -2.88 and a beta of -0.43.

Sernova (TSE:SVA) last posted its quarterly earnings results on Thursday, September 10th. The company reported C($0.01) earnings per share (EPS) for the quarter. As a group, equities research analysts predict that Sernova Corp. will post -0.08 earnings per share for the current fiscal year.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.